Picture of Medacta SA logo

MOVE — Medacta SA News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareBalancedMid CapFalling Star

Switzerland's Medacta FY 2025 revenue growth just short of estimates

Overview

Switzerland-based orthopedic solutions provider's FY 2025 revenue grew 18.5% in constant currency

FY 2025 revenue slightly missed analyst expectations

Company created 258 new jobs to foster further growth

Outlook

Medacta did not provide specific guidance for future quarters or years

Result Drivers

GEOGRAPHIC GROWTH - Substantial revenue growth across all geographic markets, led by Asia Pacific and North America

INNOVATION AND EDUCATION - Differentiating innovations and medical education drove growth across business lines

SUPPLY CHAIN OPTIMIZATION - New automated warehouse in Italy to reduce handling costs in EMEA

Key Details

MetricBeat/MissActualConsensus Estimate
FY RevenueSlight Miss*EUR 683.80 mlnEUR 687.40 mln (4 Analysts)
FY Revenue Growth18.50%
*Applies to a deviation of less than 1%; not applicable for per-share numbers. Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell" The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy" Wall Street's median 12-month price target for Medacta Group SA is CHF161.00, about 3.7% below its February 2 closing price of CHF167.20 The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 31 three months ago Press Release: ID:nEQ5SBG21a For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Medacta SA

See all news